18F-FPPRGD2 PET/CT: Pilot phase evaluation of breast cancer patients

Andrei Iagaru, Camila Mosci, Bin Shen, Frederick T. Chin, Erik Mittra, Melinda L. Telli, Sanjiv Sam Gambhir

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To present data from the first prospective pilot phase trial of breast cancer participants imaged with fluorine 18 (18F)- 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine- Aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD2), a radiopharmaceutical agent used in positron emission tomographic (PET) imaging.

Materials and Methods: The local institutional review board approved the HIPAAcompliant protocol. Written informed consent was obtained from each patient. Eight women (age range, 44-67 years; mean age, 54.3 years±8.8 [standard deviation]) with newly diagnosed or recurrent breast cancer were recruited between November 2010 and February 2011. 18F-FPPRGD2 PET/computed tomographic (CT) and 18F-fluorodeoxyglucose (FDG) PET/CT examinations were performed within 3 weeks of each other. Dynamic 18FFPPRGD2 PET and two whole-body static 18F-FPPRGD2 PET/CT scans were obtained. During this time, vital signs and electrocardiograms were recorded at regular intervals. Blood samples were obtained before the injection of 18F-FPPRGD2 and at 24 hours and 1 week after injection to evaluate for toxicity. A nonparametric version of multivariate analysis of variance was used to assess the safety outcome measures simultaneously across time points. A paired two-sample t test was performed to compare the maximum standardized uptake values (SUVmax).

Results: 18F-FPPRGD2 was well tolerated, without noticeable changes in vital signs, on electrocardiograms, or in laboratory values. A total of 30 lesions were evaluated at 18F-FDG PET/CT and 18F-FPPRGD2 PET/CT. The primary breast lesions had 18F-FPPRGD2 uptake with SUVmax of 2.4-9.4 (mean, 5.6±2.8) 60 minutes after injection, compared with 18F-FDG uptake with SUVmax of 2.8-18.6 (mean, 10.4±7.2). Metastatic lesions also showed 18FFPPRGD2 uptake, with SUVmax of 2.4-9.7 (mean, 5.0±2.3) at 60 minutes, compared with 18F-FDG uptake with SUVmax of 2.2-14.6 (mean, 6.6±4.2).

Conclusion: Data from this pilot phase study suggest that 18F-FPPRGD2 is a safe PET radiopharmaceutical agent. Evaluation of 18F-FPPRGD2 in participants with breast cancer demonstrated significant uptake in the primary lesion and in the metastases. Larger cohorts are required to confirm these preliminary findings.

Original languageEnglish (US)
Pages (from-to)549-559
Number of pages11
JournalRADIOLOGY
Volume273
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Electrons
Breast Neoplasms
Fluorodeoxyglucose F18
Radiopharmaceuticals
Vital Signs
Injections
Electrocardiography
Fluorine
2-fluoropropionyl-PEG3-E(c(RGDyk))2
Research Ethics Committees
Informed Consent
Aspartic Acid
Glycine
Arginine
Analysis of Variance
Breast
Multivariate Analysis
Outcome Assessment (Health Care)
Neoplasm Metastasis
Safety

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Iagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., & Gambhir, S. S. (2014). 18F-FPPRGD2 PET/CT: Pilot phase evaluation of breast cancer patients. RADIOLOGY, 273(2), 549-559. https://doi.org/10.1148/radiol.14140028

18F-FPPRGD2 PET/CT : Pilot phase evaluation of breast cancer patients. / Iagaru, Andrei; Mosci, Camila; Shen, Bin; Chin, Frederick T.; Mittra, Erik; Telli, Melinda L.; Gambhir, Sanjiv Sam.

In: RADIOLOGY, Vol. 273, No. 2, 01.01.2014, p. 549-559.

Research output: Contribution to journalArticle

Iagaru, A, Mosci, C, Shen, B, Chin, FT, Mittra, E, Telli, ML & Gambhir, SS 2014, '18F-FPPRGD2 PET/CT: Pilot phase evaluation of breast cancer patients', RADIOLOGY, vol. 273, no. 2, pp. 549-559. https://doi.org/10.1148/radiol.14140028
Iagaru, Andrei ; Mosci, Camila ; Shen, Bin ; Chin, Frederick T. ; Mittra, Erik ; Telli, Melinda L. ; Gambhir, Sanjiv Sam. / 18F-FPPRGD2 PET/CT : Pilot phase evaluation of breast cancer patients. In: RADIOLOGY. 2014 ; Vol. 273, No. 2. pp. 549-559.
@article{46c303b7a92b4b2487b99a0206f16c02,
title = "18F-FPPRGD2 PET/CT: Pilot phase evaluation of breast cancer patients",
abstract = "Purpose: To present data from the first prospective pilot phase trial of breast cancer participants imaged with fluorine 18 (18F)- 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine- Aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD2), a radiopharmaceutical agent used in positron emission tomographic (PET) imaging.Materials and Methods: The local institutional review board approved the HIPAAcompliant protocol. Written informed consent was obtained from each patient. Eight women (age range, 44-67 years; mean age, 54.3 years±8.8 [standard deviation]) with newly diagnosed or recurrent breast cancer were recruited between November 2010 and February 2011. 18F-FPPRGD2 PET/computed tomographic (CT) and 18F-fluorodeoxyglucose (FDG) PET/CT examinations were performed within 3 weeks of each other. Dynamic 18FFPPRGD2 PET and two whole-body static 18F-FPPRGD2 PET/CT scans were obtained. During this time, vital signs and electrocardiograms were recorded at regular intervals. Blood samples were obtained before the injection of 18F-FPPRGD2 and at 24 hours and 1 week after injection to evaluate for toxicity. A nonparametric version of multivariate analysis of variance was used to assess the safety outcome measures simultaneously across time points. A paired two-sample t test was performed to compare the maximum standardized uptake values (SUVmax).Results: 18F-FPPRGD2 was well tolerated, without noticeable changes in vital signs, on electrocardiograms, or in laboratory values. A total of 30 lesions were evaluated at 18F-FDG PET/CT and 18F-FPPRGD2 PET/CT. The primary breast lesions had 18F-FPPRGD2 uptake with SUVmax of 2.4-9.4 (mean, 5.6±2.8) 60 minutes after injection, compared with 18F-FDG uptake with SUVmax of 2.8-18.6 (mean, 10.4±7.2). Metastatic lesions also showed 18FFPPRGD2 uptake, with SUVmax of 2.4-9.7 (mean, 5.0±2.3) at 60 minutes, compared with 18F-FDG uptake with SUVmax of 2.2-14.6 (mean, 6.6±4.2).Conclusion: Data from this pilot phase study suggest that 18F-FPPRGD2 is a safe PET radiopharmaceutical agent. Evaluation of 18F-FPPRGD2 in participants with breast cancer demonstrated significant uptake in the primary lesion and in the metastases. Larger cohorts are required to confirm these preliminary findings.",
author = "Andrei Iagaru and Camila Mosci and Bin Shen and Chin, {Frederick T.} and Erik Mittra and Telli, {Melinda L.} and Gambhir, {Sanjiv Sam}",
year = "2014",
month = "1",
day = "1",
doi = "10.1148/radiol.14140028",
language = "English (US)",
volume = "273",
pages = "549--559",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - 18F-FPPRGD2 PET/CT

T2 - Pilot phase evaluation of breast cancer patients

AU - Iagaru, Andrei

AU - Mosci, Camila

AU - Shen, Bin

AU - Chin, Frederick T.

AU - Mittra, Erik

AU - Telli, Melinda L.

AU - Gambhir, Sanjiv Sam

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To present data from the first prospective pilot phase trial of breast cancer participants imaged with fluorine 18 (18F)- 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine- Aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD2), a radiopharmaceutical agent used in positron emission tomographic (PET) imaging.Materials and Methods: The local institutional review board approved the HIPAAcompliant protocol. Written informed consent was obtained from each patient. Eight women (age range, 44-67 years; mean age, 54.3 years±8.8 [standard deviation]) with newly diagnosed or recurrent breast cancer were recruited between November 2010 and February 2011. 18F-FPPRGD2 PET/computed tomographic (CT) and 18F-fluorodeoxyglucose (FDG) PET/CT examinations were performed within 3 weeks of each other. Dynamic 18FFPPRGD2 PET and two whole-body static 18F-FPPRGD2 PET/CT scans were obtained. During this time, vital signs and electrocardiograms were recorded at regular intervals. Blood samples were obtained before the injection of 18F-FPPRGD2 and at 24 hours and 1 week after injection to evaluate for toxicity. A nonparametric version of multivariate analysis of variance was used to assess the safety outcome measures simultaneously across time points. A paired two-sample t test was performed to compare the maximum standardized uptake values (SUVmax).Results: 18F-FPPRGD2 was well tolerated, without noticeable changes in vital signs, on electrocardiograms, or in laboratory values. A total of 30 lesions were evaluated at 18F-FDG PET/CT and 18F-FPPRGD2 PET/CT. The primary breast lesions had 18F-FPPRGD2 uptake with SUVmax of 2.4-9.4 (mean, 5.6±2.8) 60 minutes after injection, compared with 18F-FDG uptake with SUVmax of 2.8-18.6 (mean, 10.4±7.2). Metastatic lesions also showed 18FFPPRGD2 uptake, with SUVmax of 2.4-9.7 (mean, 5.0±2.3) at 60 minutes, compared with 18F-FDG uptake with SUVmax of 2.2-14.6 (mean, 6.6±4.2).Conclusion: Data from this pilot phase study suggest that 18F-FPPRGD2 is a safe PET radiopharmaceutical agent. Evaluation of 18F-FPPRGD2 in participants with breast cancer demonstrated significant uptake in the primary lesion and in the metastases. Larger cohorts are required to confirm these preliminary findings.

AB - Purpose: To present data from the first prospective pilot phase trial of breast cancer participants imaged with fluorine 18 (18F)- 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine- Aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD2), a radiopharmaceutical agent used in positron emission tomographic (PET) imaging.Materials and Methods: The local institutional review board approved the HIPAAcompliant protocol. Written informed consent was obtained from each patient. Eight women (age range, 44-67 years; mean age, 54.3 years±8.8 [standard deviation]) with newly diagnosed or recurrent breast cancer were recruited between November 2010 and February 2011. 18F-FPPRGD2 PET/computed tomographic (CT) and 18F-fluorodeoxyglucose (FDG) PET/CT examinations were performed within 3 weeks of each other. Dynamic 18FFPPRGD2 PET and two whole-body static 18F-FPPRGD2 PET/CT scans were obtained. During this time, vital signs and electrocardiograms were recorded at regular intervals. Blood samples were obtained before the injection of 18F-FPPRGD2 and at 24 hours and 1 week after injection to evaluate for toxicity. A nonparametric version of multivariate analysis of variance was used to assess the safety outcome measures simultaneously across time points. A paired two-sample t test was performed to compare the maximum standardized uptake values (SUVmax).Results: 18F-FPPRGD2 was well tolerated, without noticeable changes in vital signs, on electrocardiograms, or in laboratory values. A total of 30 lesions were evaluated at 18F-FDG PET/CT and 18F-FPPRGD2 PET/CT. The primary breast lesions had 18F-FPPRGD2 uptake with SUVmax of 2.4-9.4 (mean, 5.6±2.8) 60 minutes after injection, compared with 18F-FDG uptake with SUVmax of 2.8-18.6 (mean, 10.4±7.2). Metastatic lesions also showed 18FFPPRGD2 uptake, with SUVmax of 2.4-9.7 (mean, 5.0±2.3) at 60 minutes, compared with 18F-FDG uptake with SUVmax of 2.2-14.6 (mean, 6.6±4.2).Conclusion: Data from this pilot phase study suggest that 18F-FPPRGD2 is a safe PET radiopharmaceutical agent. Evaluation of 18F-FPPRGD2 in participants with breast cancer demonstrated significant uptake in the primary lesion and in the metastases. Larger cohorts are required to confirm these preliminary findings.

UR - http://www.scopus.com/inward/record.url?scp=84910047513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910047513&partnerID=8YFLogxK

U2 - 10.1148/radiol.14140028

DO - 10.1148/radiol.14140028

M3 - Article

C2 - 25033190

AN - SCOPUS:84910047513

VL - 273

SP - 549

EP - 559

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -